Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells $18,636.80 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $11.20, for a total transaction of $18,636.80. Following the completion of the transaction, the chief executive officer now directly owns 77,454 shares of the company’s stock, valued at $867,484.80. This trade represents a 2.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock traded down $0.31 on Wednesday, hitting $10.68. The company had a trading volume of 108,460 shares, compared to its average volume of 107,467. The stock’s 50-day moving average is $9.09 and its two-hundred day moving average is $10.10. Atara Biotherapeutics, Inc. has a twelve month low of $6.50 and a twelve month high of $39.50. The firm has a market cap of $61.52 million, a P/E ratio of -0.43 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share. Equities research analysts predict that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ATRA shares. Mizuho raised Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Hold” and an average target price of $16.67.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATRA. Geode Capital Management LLC lifted its stake in Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares in the last quarter. State Street Corp raised its holdings in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares in the last quarter. FMR LLC boosted its holdings in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.